Newronika develops an adaptive deep brain stimulation (DBS) platform that integrates real-time patient neural data and machine learning to optimize therapy and reduce side effects. The company holds a CE Mark and has received an Investigational Device Exemption (IDE) from the FDA, and recently received a grant from The Michael J. Fox Foundation. The €13.6 million Series B financing will accelerate clinical validation and commercialization of its proprietary adaptive DBS system. Newronika plans to advance its product pipelines, recruit top-tier talent, and establish strategic collaborations to strengthen its position at the intersection of medical device engineering and neuroscience. Headquartered in Milan, Italy, the company positions its technology as a next-generation personalized neuromodulation solution. The funding supports Newronika's push toward broader clinical and commercial deployment. Newronika develops an adaptive deep brain stimulation (DBS) system, the Alpha-DBS, designed to automatically adjust therapy to patients’ needs. The company has a CE-marked deep brain stimulation system and is developing proprietary adaptive DBS technology with licensed patents and published initial clinical data. The €2.5M EIC Accelerator grant will fund a multi-center European pivotal trial comparing adaptive DBS to conventional DBS in advanced Parkinson’s disease patients and support product development for European market readiness. Newronika was founded in 2009 by a multidisciplinary team led by Dr. Alberto Priori with participation from Fondazione IRCCSS Ca’ Granda Ospedale Maggiore Policlinico and the University of Milan. The company is venture-backed and is completing feasibility trials at several leading DBS centers. Its platform technology is positioned for application to other central nervous system disorders. Newronika is a Milan-based neurotech startup that has developed an implantable medical device for deep brain stimulation using a retroaction “closed loop” system. The company's technology is initially targeted at patients affected by Parkinson’s disease. Newronika is a spin-off of Policlinico di Milano and Università degli Studi di Milano and is led by CEO Lorenzo Rossi and CFO Alain Garcinuño. It raised €8.4m in funding to advance its clinical and regulatory work. Proceeds will be used to complete its first human clinical study and to obtain CE marking and IDE acknowledgement from the FDA. The company says it is ready to start the clinical experiment to make the technology available to patients. Newronika develops a patented closed‑loop Deep Brain Stimulation (DBS) technology that records brain activity and modulates neurostimulation based on Parkinson’s fluctuations and patient conditions. The company’s core product is an implantable device for neuromodulation therapy aimed at treating Parkinson’s disease. Newronika is a spin‑off from Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano and Università degli Studi di Milano. It has completed a first human feasibility and safety study involving 17 patients, with results to be released soon. The firm intends to use newly raised funds to continue clinical studies, finalize development of its implantable device and complete the regulatory clinical path. The company holds patented technology developed from research by Prof. Alberto Priori and Lorenzo Rossi, PhD.

Total raised

$30M

Funding rounds

4

Latest round

Series B

Latest activity

Feb 2025